Preclinical studies reported that ciproxifan, an imidazole-based H3R antagonist demonstrated improvements in hyperactivity and associated memory impairment after administration of this drug in a mouse model of AD (Bardgett et al., 2011). Here, HRH3 is linked to memory impairment.